FormulaFolio Investments LLC Has $212,000 Holdings in Becton Dickinson and Co (BDX)

FormulaFolio Investments LLC decreased its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 73.2% in the first quarter, HoldingsChannel.com reports. The firm owned 849 shares of the medical instruments supplier’s stock after selling 2,318 shares during the quarter. FormulaFolio Investments LLC’s holdings in Becton Dickinson and were worth $212,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in BDX. Harvest Group Wealth Management LLC bought a new position in Becton Dickinson and during the first quarter worth about $25,000. Oregon Public Employees Retirement Fund lifted its stake in Becton Dickinson and by 22,485.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 6,545,502 shares during the period. Pinnacle Financial Partners Inc. bought a new position in Becton Dickinson and during the first quarter worth about $29,000. RPG Investment Advisory LLC bought a new position in Becton Dickinson and during the first quarter worth about $32,000. Finally, Nalls Sherbakoff Group LLC bought a new position in Becton Dickinson and during the fourth quarter worth about $34,000. Hedge funds and other institutional investors own 84.03% of the company’s stock.

NYSE BDX opened at $235.68 on Thursday. The company has a market cap of $63.11 billion, a PE ratio of 21.02, a PEG ratio of 1.75 and a beta of 1.16. The company has a debt-to-equity ratio of 0.82, a current ratio of 0.96 and a quick ratio of 0.59. Becton Dickinson and Co has a 1-year low of $208.62 and a 1-year high of $265.87.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. The business had revenue of $4.20 billion during the quarter, compared to analyst estimates of $4.25 billion. Becton Dickinson and had a net margin of 5.88% and a return on equity of 14.58%. Becton Dickinson and’s revenue for the quarter was down .6% compared to the same quarter last year. During the same quarter last year, the business posted $2.65 earnings per share. Equities analysts predict that Becton Dickinson and Co will post 11.7 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Friday, June 7th will be issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.31%. The ex-dividend date is Thursday, June 6th. Becton Dickinson and’s dividend payout ratio is currently 27.97%.

Several research firms have recently weighed in on BDX. Zacks Investment Research raised shares of Becton Dickinson and from a “sell” rating to a “hold” rating in a report on Monday. Wells Fargo & Co dropped their price objective on shares of Becton Dickinson and from $280.00 to $265.00 and set an “outperform” rating for the company in a report on Monday, May 13th. Barclays raised shares of Becton Dickinson and from an “equal weight” rating to an “overweight” rating and set a $266.00 price objective for the company in a report on Monday, May 13th. BMO Capital Markets dropped their price objective on shares of Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating for the company in a report on Friday, May 10th. Finally, Morgan Stanley dropped their price objective on shares of Becton Dickinson and from $255.00 to $250.00 and set an “equal weight” rating for the company in a report on Friday, May 10th. Six equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Becton Dickinson and has a consensus rating of “Buy” and an average target price of $255.31.

In related news, EVP Betty D. Larson sold 1,700 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $224.97, for a total value of $382,449.00. Following the completion of the sale, the executive vice president now owns 11,493 shares of the company’s stock, valued at $2,585,580.21. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Vincent A. Forlenza sold 11,340 shares of the firm’s stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $250.40, for a total transaction of $2,839,536.00. Following the completion of the sale, the chief executive officer now directly owns 227,250 shares of the company’s stock, valued at approximately $56,903,400. The disclosure for this sale can be found here. In the last three months, insiders sold 31,384 shares of company stock valued at $7,901,023. 0.12% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/05/23/formulafolio-investments-llc-has-212000-holdings-in-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Story: Average Daily Trade Volume – What You Need to Know

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.